Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Toxic Financier's Lawyer is PTSC's Representative of PDS

IMO a RS would be acceptable once the USPTO re-examination is completed and the patents are approved. At least it would move PTSC off of the BB on to a better exchange where PTSC could get better visibility and large investors can evaluate us. IMO a successful RS is totally dependent on the company, if the fundamentals are in place it will work, if they are not in place it wont. PTSC can always do a forward split 1 for 2 or 1 for 3 as they become more successful.

I worked at a company for 25 years that was growing the entire time I was there. They made several forward splits in the stock 1 for 2. They are a very successful company.

All the best,

Steve

Share
New Message
Please login to post a reply